These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21874663)

  • 1. Granting you success.
    Beylin D; Chrisman CJ; Weingarten M
    Nat Biotechnol; 2011 Jul; 29(7):567-70. PubMed ID: 21874663
    [No Abstract]   [Full Text] [Related]  

  • 2. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 3. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 4. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 5. Germany biotech gets second chance.
    Sheridan C
    Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 8. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotechs get $1 billion windfall in R&D tax credits.
    Thiel K
    Nat Biotechnol; 2009 Dec; 27(12):1066. PubMed ID: 20010563
    [No Abstract]   [Full Text] [Related]  

  • 10. More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
    Rinaldi A
    EMBO Rep; 2006 Feb; 7(2):133-6. PubMed ID: 16452923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 12. Superscience me!
    Nat Biotechnol; 2007 Jun; 25(6):604. PubMed ID: 17557082
    [No Abstract]   [Full Text] [Related]  

  • 13. China pushes liver proteomics.
    Jia H; Louët S
    Nat Biotechnol; 2004 Feb; 22(2):136. PubMed ID: 14755276
    [No Abstract]   [Full Text] [Related]  

  • 14. First U.S.-Russian business venture in closed nuclear city.
    Lopatto J; Wilkes B
    Health Phys; 2004 Feb; 86(2):212-3. PubMed ID: 14744060
    [No Abstract]   [Full Text] [Related]  

  • 15. How the EU can fund your company.
    Gilbert N
    Nat Biotechnol; 2007 Jan; 25(1):21-4. PubMed ID: 17294566
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

  • 17. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 18. New biotech oasis?
    Sheridan C
    Nat Biotechnol; 2005 Aug; 23(8):919. PubMed ID: 16114121
    [No Abstract]   [Full Text] [Related]  

  • 19. The doc and the dough.
    Bleich HL
    MD Comput; 1992; 9(5):282-3. PubMed ID: 1522788
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantifying the dream: valuation approaches in biotechnology.
    Papadopoulos S
    Nat Biotechnol; 1998 May; 16 Suppl():55-6. PubMed ID: 9591273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.